Date: 2017-05-16
Type of information: Grant
Company: Crispr Therapeutics (Switzerland - UK)
Investors: Target ALS Foundation (USA)
Amount:
Funding type: grant
Planned used:
- This two-year grant will support preclinical discovery and validation of CRISPR/Cas9-based therapeutic approaches directed to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). CRISPR Therapeutics will collaborate with Dr. Laura Ranum and Dr. Eric Wang, researchers at the University of Florida in the Center for NeuroGenetics and the Department of Molecular Genetics & Microbiology, to test CRISPR/Cas9 gene-editing strategies in disease models developed by Dr. Ranum and Dr. Wang.
Others:
- • On May 16, 2017, CRISPR Therapeutics announced that Target ALS Foundation, a non-profit organization dedicated to accelerating new treatments for amyotrophic lateral sclerosis (ALS), has awarded a two-year grant to CRISPR Therapeutics and its collaborators to support preclinical discovery and validation of CRISPR/Cas9-based therapeutic approaches directed to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Therapeutic area: Neurodegenerative diseases
Is general: Yes
